Positive News SentimentPositive NewsNYSE:BVS Bioventus (BVS) Stock Price, News & Analysis $9.53 -0.13 (-1.35%) (As of 09/6/2024 ET) Add Compare Share Share Today's Range$9.12▼$9.7350-Day Range$5.73▼$10.0552-Week Range$2.82▼$10.26Volume411,750 shsAverage Volume375,661 shsMarket Capitalization$754.45 millionP/E RatioN/ADividend YieldN/APrice Target$10.33 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsTrendsStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsTrends Get Bioventus alerts: Email Address Bioventus MarketRank™ Stock AnalysisAnalyst RatingBuy3.00 Rating ScoreUpside/Downside8.4% Upside$10.33 Price TargetShort InterestN/ADividend StrengthN/ASustainabilityN/ANews SentimentN/AInsider TradingAcquiring Shares$902,025 Bought Last QuarterProj. Earnings Growth12.50%From $0.40 to $0.45 Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.1.90 out of 5 starsMedical Sector564th out of 910 stocksSurgical & Medical Instruments Industry65th out of 95 stocks 1.5 Analyst's Opinion Consensus RatingBioventus has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 3 buy ratings, no hold ratings, and no sell ratings.Amount of Analyst CoverageBioventus has only been the subject of 2 research reports in the past 90 days.Read more about Bioventus' stock forecast and price target. Previous Next N/A Short Interest Short InterestThere is no current short interest data available for BVS. Previous Next 0.0 Dividend Strength Dividend YieldBioventus does not currently pay a dividend.Dividend GrowthBioventus does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for BVS. Previous Next 3.8 News and Social Media Coverage News SentimentBioventus has a news sentiment score of 1.88. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.55 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 1 news article for Bioventus this week, compared to 1 article on an average week.Search Interest9 people have searched for BVS on MarketBeat in the last 30 days. This is an increase of 350% compared to the previous 30 days.MarketBeat Follows10 people have added Bioventus to their MarketBeat watchlist in the last 30 days. This is an increase of 900% compared to the previous 30 days. Previous Next 5.0 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Bioventus insiders have bought 291.18% more of their company's stock than they have sold. Specifically, they have bought $902,025.00 in company stock and sold $230,591.00 in company stock.Percentage Held by Insiders32.90% of the stock of Bioventus is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions62.94% of the stock of Bioventus is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Bioventus' insider trading history. Previous Next 1.3 Earnings and Valuation Earnings GrowthEarnings for Bioventus are expected to grow by 12.50% in the coming year, from $0.40 to $0.45 per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Bioventus is -27.23, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Bioventus is -27.23, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioBioventus has a P/B Ratio of 4.09. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.Read more about Bioventus' valuation and earnings. Previous Next See Top Rated MarketRank™ Stocks Here Ad Golden CrestBiden’s Capital Gains Tax to Devastate Savings!Don't let the corrupt elites dictate your future—ACT NOW! This guide is your first step towards financial independence and security.>> Get Your FREE Wealth Protection Guide << About Bioventus Stock (NYSE:BVS)Bioventus Inc., a medical device company, focuses on developing and commercializing treatments that engage and enhance the body's natural healing process in the United States and internationally. The company's product portfolio includes pain treatments, which comprise non-surgical pain injection therapies, as well as peripheral nerve stimulation products, such as Durolane, GELSYN-3, and SUPARTZ for the treatment of knee osteoarthritis and Stimrouter to treat chronic peripheral pain. Its surgical solutions comprise bone graft substitutes that increase bone formation to stimulate bone healing in spinal fusions and other orthopedic surgeries; and ultrasonic products used for precise bone cutting and sculpting, soft tissue management, and tissue debridement, in various surgeries, including minimally invasive applications. The company's product include, Osteoamp, an allograft-derived bone graft for bone grafting procedures; Exponent matrix for posterolateral spine procedures; Purebone for bone grafting procedures; Signafuse bone graft; Interfuse bone graft; Osteomatrix+ synthetic bone graft; Extractor for autologous cell and bone marrow extraction; reficio bone matrix; nexus ultrasonic surgical system; bonescalpel surgical solution; SonaStar for surgical procedures; and SonicOne ultrasonic cleansing and debridement system. The company's restorative therapies include a bone stimulation system and devices to help patients regain leg or hand function due to stroke, multiple sclerosis, or other central nervous system disorders. Its products include exogen, a bone healing system; L300 GO, a foot drop system; H200 rehabilitation system; Vector, a body weight support system; and Bioness integrated therapy system. It developing Talisman pulse generator and receiver for peripheral nerve stimulation. The company was founded in 2011 and is headquartered in Durham, North Carolina.Read More BVS Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart BVS Stock News HeadlinesAugust 21, 2024 | insidertrades.comBioventus Inc. (NYSE:BVS) Director John A. Bartholdson Acquires 25,500 SharesAugust 21, 2024 | insidertrades.comBioventus Inc. (NYSE:BVS) Director John A. Bartholdson Acquires 80,000 SharesSeptember 7, 2024 | Porter & Company (Ad)War on Elon Escalates… A radical, potentially game-changing technology that threatens to destroy the trillion-dollar, “green energy” grift of the elites. And yet, while it threatens their wealth and power, it could be transformational for both the U.S. economy and your wealth.August 29, 2024 | finance.yahoo.comBioventus and Pool have been highlighted as Zacks Bull and Bear of the DayAugust 12, 2024 | seekingalpha.comBioventus Inc. (BVS) Q2 2024 Earnings Call TranscriptAugust 12, 2024 | seekingalpha.comHealing Numbers, Hurting Valuation: Bioventus' Mixed Bag In Q2 2024August 7, 2024 | globenewswire.comBioventus to Present at the Canaccord Genuity 44th Annual Global Growth ConferenceAugust 6, 2024 | benzinga.comYum China Posts Upbeat Earnings, Joins Clear Secure, TG Therapeutics, Bioventus And Other Big Stocks Moving Higher On TuesdaySeptember 7, 2024 | Porter & Company (Ad)War on Elon Escalates… A radical, potentially game-changing technology that threatens to destroy the trillion-dollar, “green energy” grift of the elites. And yet, while it threatens their wealth and power, it could be transformational for both the U.S. economy and your wealth.August 6, 2024 | marketwatch.comBioventus Shares Rise on Upbeat 2Q, Guidance BoostAugust 6, 2024 | globenewswire.comBioventus Reports Second Quarter Financial ResultsAugust 2, 2024 | globenewswire.comBIOVENTUS ALERT: Bragar Eagel & Squire, P.C. is Investigating Bioventus Inc. on Behalf of Long-Term Stockholders and Encourages Investors to Contact the FirmJuly 30, 2024 | globenewswire.comBioventus to Report Second Quarter of Fiscal Year 2024 Financial Results on August 6, 2024July 20, 2024 | bizjournals.comDurham company agrees to $15 million settlement in shareholder lawsuitMay 23, 2024 | investorplace.com3 Stocks Under $10 With Mammoth Growth ProspectsMay 8, 2024 | finance.yahoo.comBioventus Inc. (NASDAQ:BVS) Q1 2024 Earnings Call TranscriptMay 8, 2024 | bizjournals.comDurham public company reports earnings boost after CEO shakeupMay 8, 2024 | finance.yahoo.comBioventus Inc (BVS) Q1 2024 Earnings Call Transcript Highlights: Strong Start with Significant ...See More Headlines Receive BVS Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Bioventus and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings8/06/2024Today9/07/2024Next Earnings (Estimated)11/05/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNYSE SectorMedical Industry Surgical & medical instruments Sub-IndustryMedical Equipment Current SymbolNYSE:BVS CUSIPN/A CIK1665988 Webwww.bioventus.com Phone919-474-6700FaxN/AEmployees1,200Year FoundedN/APrice Target and Rating Average Stock Price Target$10.33 High Stock Price Target$12.00 Low Stock Price Target$7.00 Potential Upside/Downside+8.4%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage3 Analysts Profitability EPS (Most Recent Fiscal Year)($0.35) Trailing P/E RatioN/A Forward P/E Ratio23.83 P/E GrowthN/ANet Income$-156,230,000.00 Net Margins-7.82% Pretax Margin-11.39% Return on Equity14.39% Return on Assets3.83% Debt Debt-to-Equity Ratio1.82 Current Ratio1.33 Quick Ratio0.96 Sales & Book Value Annual Sales$536.89 million Price / Sales1.41 Cash Flow$0.75 per share Price / Cash Flow12.70 Book Value$2.33 per share Price / Book4.09Miscellaneous Outstanding Shares79,166,000Free Float53,120,000Market Cap$754.45 million OptionableNot Optionable Beta0.89 A Guide To High-Short-Interest StocksMarketBeat's analysts have just released their top five short plays for September 2024. Learn which stocks have the most short interest and how to trade them. Click the link below to see which companies made the list.Get This Free Report Key ExecutivesMr. Mark L. Singleton (Age 54)Senior VP & CFO Comp: $740.04kMr. Anthony D'Adamio (Age 63)Senior VP, General Counsel & Corporate Secretary Comp: $705.38kMr. Robert E. Claypoole (Age 52)President, CEO & Director Mr. Mike Crowe B.S.M.B.A., Senior Vice President of OperationsMr. David CrawfordVice President of Investor Relations & TreasurerMs. Katrina J. Church J.D. (Age 62)Senior VP & Chief Compliance Officer Ms. Helen LeupoldSenior VP & Chief Human Resources OfficerMr. Larry ChenManaging Director of China & Asia PacificMore ExecutivesKey CompetitorsEnvistaNYSE:NVSTTandem Diabetes CareNASDAQ:TNDMInari MedicalNASDAQ:NARILivaNovaNASDAQ:LIVNEnovisNYSE:ENOVView All CompetitorsInsiders & InstitutionsNantahala Capital Management LLCSold 467,698 shares on 8/20/2024Ownership: 6.743%John A BartholdsonBought 25,500 shares on 8/19/2024Total: $218,025.00 ($8.55/share)John A BartholdsonBought 80,000 shares on 8/16/2024Total: $684,000.00 ($8.55/share)The Manufacturers Life Insurance Company Bought 15,136 shares on 8/15/2024Ownership: 0.019%Susquehanna Portfolio Strategies LLCSold 18,750 shares on 8/15/2024Ownership: 0.018%View All Insider TransactionsView All Institutional Transactions BVS Stock Analysis - Frequently Asked Questions How have BVS shares performed this year? Bioventus' stock was trading at $5.27 on January 1st, 2024. Since then, BVS shares have increased by 80.8% and is now trading at $9.53. View the best growth stocks for 2024 here. How were Bioventus' earnings last quarter? Bioventus Inc. (NYSE:BVS) announced its quarterly earnings data on Tuesday, August, 6th. The company reported $0.19 EPS for the quarter, beating the consensus estimate of $0.07 by $0.12. The firm had revenue of $151.22 million for the quarter, compared to analyst estimates of $137.70 million. Bioventus had a negative net margin of 7.82% and a positive trailing twelve-month return on equity of 14.39%. When did Bioventus IPO? Bioventus (BVS) raised $126 million in an IPO on Thursday, February 11th 2021. The company issued 7,400,000 shares at $16.00-$18.00 per share. Morgan Stanley, J.P. Morgan, Goldman Sachs and Canaccord Genuity served as the underwriters for the IPO. Who are Bioventus' major shareholders? Bioventus' top institutional shareholders include Nantahala Capital Management LLC (6.74%), Renaissance Technologies LLC (0.64%), Marshall Wace LLP (0.42%) and American Century Companies Inc. (0.21%). Insiders that own company stock include John A Bartholdson, Juniper Investment Company, Ll, William A Hawkins, Anthony P Bihl III, Anthony D'adamio, John Nosenzo, Mark Leonard Singleton, Kenneth Michael Reali and Katrina J Church. View institutional ownership trends. How do I buy shares of Bioventus? Shares of BVS stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NYSE:BVS) was last updated on 9/7/2024 by MarketBeat.com Staff From Our PartnersPerfect Crypto Buying Opportunity for 50 CentsWhen cryptos take a hit, the mom and pop investors run for the hills. But the top investors keep buying wit...Crypto 101 Media | SponsoredThe solution to fast food’s wage hike crisisShake Shack will be closing six California locations in response to the recent $20/hour minimum wage increase,...Deal Maker | SponsoredPre-IPO| 32,481% Growth: First Disruption to $martphones in 15 Years🤳45M Users | 32,481% Growth Rate Get in on the biggest disruption to smartphones in over a decade. Reg A inv...Mode Mobile | SponsoredBiden’s Capital Gains Tax to Devastate Savings!Don't let the corrupt elites dictate your future—ACT NOW! This guide is your first step towards financial inde...Golden Crest | SponsoredTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock This $2 trillion D.C. shock is NOT abou...Timothy Sykes | SponsoredSay Goodbye to the US DollarThe warning signs are everywhere… According to experts, the United States Dollar is "as good as doomed." ...Sasco Gold LLC | SponsoredChina Stockpiling Gold “Like No Tomorrow”For 18 consecutive months, China’s central bank has increased its gold reserve. The country, with a populat...True Gold Republic | SponsoredMy grim warning about AI stocksToday, I’m warning of another looming catastrophe. Only this time, it’s not in pot stocks, cryptos, or U.S....Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Bioventus Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Bioventus With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.